Non-small cell lung cancer is one of the most common malignant tumours in China.
The Chinese pharmaceutical company said it plans to initiate the Phase II Clinical Trial Protocol in the second half of 2008. TFN.newsdesk@thomson.com npr/slj
COPYRIGHT
Copyright Thomson Financial News Limited 2008. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
MMMM

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index